BIOPHYTIS (EPA:ALBPS) - Biophytis to Present at the 15th International Congress of the European Geriatric Medicine Society in Krakow, Poland
Transparency directive : regulatory news
Click here to download pdf version
Biophytis to Present at the 15th International Congress of the European
Geriatric Medicine Society in Krakow, Poland
Paris (France), Cambridge (Massachusetts, United States), September 26, 2019,
8:00 AM CEST - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage
biotechnology company focused on the development of drug candidates for the
treatment of age-related diseases, announces that Waly Dioh, VP Clinical
Development, will make a presentation titled, "Evaluation of Safety and
Efficacy of BIO101, a Mas Receptor Activating Drug for Sarcopenia: A
Double-blind, Placebo Controlled, Randomized Clinical Trial" at the 15th
International Congress of the European Geriatric Medicine (EuGMS). The Congress
is taking place between 25th and 27th September 2019 in Krakow, Poland.
Biophytis' clinical development plan for Sarconeos (BIO101) for the treatment
of sarcopenia comprises:
* SARA-PK, a Phase 1 clinical trial that showed safety and tolerability in
older healthy volunteers. The trial completed in 2017.
* SARA-OBS, an observational trial that was completed in Q2 2019 with the last
patient out, and
* SARA-INT, an ongoing international Phase 2b trial with a 6-month follow-up
period that is currently recruiting patients in the US and Europe. The
primary endpoint of the study is the 400-meter walking test gait speed.
In his presentation Mr. Dioh will:
* Outline the SARA-OBS study, which was designed to characterize, pre-recruit
and confirm the optimal patient population for the SARA-INT trial, and
* Provide data on the preliminary baseline characteristics and changes from
baseline of the first set of SARA-OBS patients.
In addition, insights on the SARA-INT recruitment strategies, including
inclusion criteria, as well as the baseline characteristics of the first
patients, will be discussed.
The presentation will be made today at 2:30 PM CEST.
About Sarconeos (BIO101)
Biophytis's lead drug candidate, Sarconeos (BIO101), is an orally administered
small molecule for the treatment of neuromuscular diseases. Sarconeos (BIO101)
is a plant-derived pharmaceutical-grade purification of 20- hydroxyecdysone.
Pre-clinical studies have shown that (Sarconeos) BIO101 stimulates biological
resilience through activation of the MAS receptor, which suggests preservation
of muscle strength, function and mobility in various muscular wasting
conditions. Biophytis is currently testing Sarconeos (BIO101) in a global,
randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical
trial (SARA-INT) on patients with sarcopenia, a disease of ageing characterized
by a loss of muscle mass, strength and function in elderly people leading to
mobility disabilities, an increased risk of adverse health events and potential
Biophytis is a clinical-stage biotechnology company focused on developing
therapeutics that slow the degenerative processes associated with aging and
improve functional outcomes for patients suffering from age-related diseases,
with a primary focus on neuromuscular diseases.
Biophytis' lead drug candidate, Sarconeos (BIO101), is an orally administered
small molecule, which is currently in a Phase 2b clinical trial for sarcopenia
(SARA-INT) in the US and Europe. Sarconeos (BIO101) is also being developed for
the treatment of Duchenne muscular dystrophy (DMD). Biophytis expects Sarconeos
(BIO101) to be ready to enter the clinic for DMD in 2020.
Biophytis is headquartered in Paris, France, and has offices in Cambridge,
Massachusetts. The Company's ordinary shares are listed on Euronext Growth
Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit
This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf- france.org) or on Biophytis' website (www.biophytis.com).
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to securities
of Biophytis in any country. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements and estimates,
which speak only as of the date hereof. Other than as required by applicable
law, Biophytis undertakes no obligation to update or revise the information
contained in this press release. This press release has been prepared in both
French and English. In the event of any differences between the two texts, the
French language version shall prevail.
Biophytis Investor Relations Contact
Daniel Schneiderman, CFO
Tel: +1 (857) 220-9720
U.S. Media Contact
LifeSci Public Relations
Cherilyn Cecchini, M.D.
Tel: +1 (646) 876-5196
Europe Media Contact
Citigate Dewe Rogerson
Quentin Dussart / Sylvie Berrebi / Nathaniel Dahan / David Dible
Tel: +33 (0)1 55 30 70 91 / +44 (0)20 76389571
Source : Biophytis